When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Is a VIVUS Buyout Still on the Table? And if So, by Whom? - AOL

   www.aol.com/news/2012-10-12-is-a-vivus-buyout...

   The pieces of the puzzle are starting to fall into place for VIVUS (NASDAQ: VVUS) and its potential blockbuster anti-obesity drug, Qsymia. The drug, which was approved by the Food and Drug ...

3. What Are the Biggest Risks Facing VIVUS Today? - AOL

   www.aol.com/2012/11/16/what-are-the-biggest...

   VIVUS (NAS: VVUS) investors may have breathed a sigh of relief after the company's obesity drug, Qsymia, gained approval from the Food and Drug Administration this summer -- but passing this ...

4. 3 Things to Watch With VIVUS - AOL

   www.aol.com/news/2012-08-30-3-things-to-watch...

   VIVUS (NAS: VVUS) investors hope the company's FDA approval signals an era of slimmer waistlines. But the market seems to think this small drugmaker is trying to peddle a prescription-only Olestra ...

5. Buy, Sell, or Hold: VIVUS

   www.aol.com/news/2012-06-12-buy-sell-or-hold...

   For premium support please call: 800-290-4726 more ways to reach us

6. VVUS: New Ideas for Established Portfolio

   www.aol.com/news/vvus-ideas-established...

   We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic ...

7. Areas That VIVUS Investors Must Watch - AOL

   www.aol.com/2012/11/13/areas-vivus-investors...

   For premium support please call: 800-290-4726 more ways to reach us

8. Down 20%: What Is VIVUS' Market Opportunity? - AOL

   www.aol.com/news/2012-11-06-down-20-what-is...

   VIVUS (NAS: VVUS) may have beaten its rival Arena Pharmaceuticals (NAS: ARNA) in getting an obesity drug on the market first, but its shares plunged almost 20% this morning after reporting ...

9. 3 Reasons to Sell: VIVUS - AOL

   www.aol.com/news/2012-08-22-3-reasons-to-sell...

   For premium support please call: 800-290-4726 more ways to reach us